ClinicalTrials.gg
RecruitingNCT06888128STARLIGHTUpdated Jan 22, 2026

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

A Phase 2 interventional study of Psilocybin 15mg and Psilocybin 25mg in PTSD, sponsored by Baylor College of Medicine. Recruiting at 1 site in United States. Open to participants aged 21 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Baylor College of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
21 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
15th of 20
15 · median 33
Started
2025
with 4 others
Phase 2
10 of 20
5 open now
Primary completion
2026-12
later than 5 of 15 live
Registered
12th of 20
by date
Lead sponsor
1 of 20
Baylor College of Medicine

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 15th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 5 of the 15 other live ones, and was the 12th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 21 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • veterans
  • psilocybin
  • trauma
  • psychedelic
04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a United States Military Veteran
  • Have at least a high-school level of education or equivalent (e.g. GED).
  • Have a current diagnosis of Post-traumatic Stress Disorder
  • Have a CAPS-5 total severity score of ≥23 at baseline
  • SSRIs will be allowable so long as participants are on a stable regimen for a period of 3 months.
  • Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least 2 months prior to screening and is expected to remain stable during participation in the study.
  • Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an (ECG), and routine medical blood and urinalysis laboratory tests
  • No use of hallucinogens in the past 3 months and no history of regular or frequent use of hallucinogens

Exclusion criteria

Exclusion Criteria:

  • General medical exclusion criteria:

    • Individuals who are pregnant or nursing; individuals who are of and sexually active who are not practicing a highly effective means of
    • Individuals with partners of childbearing potential who are sexually active and not practicing a highly effective means of contraception
    • Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a abnormality (e.g., atrial fibrilation), prolonged (i.e., QTc > 450 msec), artificial heart valve, or in the past year • Systolic blood pressure (SBP) > 139 mm HG; diastolic blood pressure (DBP) > 89 mm HG; heart rate (HR) > 90 bpm.
    • Epilepsy with history of seizures
    • Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of symptoms of hypoglycemia
  • Psychiatric Exclusion Criteria:

    • Current or past history of meeting criteria for schizophrenia spectrum or other psychotic disorders (except substance/medication-induced or due to another medical condition), or Bipolar I or II Disorder
    • Current or history within six months of meeting DSM-5 criteria for a moderate or severe alcohol, tobacco, caffeine, or other drug use disorder; if a regular smoker, they must agree to use a nicotine patch on the day of dosing as smoking will not be allowed on these sessions
    • Have a first degree relative with schizophrenia spectrum or other psychotic disorders including substance/medication-induced or due to another medical condition
    • Risk for acute suicidality as determined by clinician judgment (C-SSRS)
    • Has a psychiatric condition which precludes the establishment of therapeutic rapport as evidenced by long-term patterns of unstable relationships, history of significant stress-related paranoia, and identity disturbances
    • History of a medically significant suicide attempt
    • Current MAOI antidepressant use
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Psilocybin-assisted therapy

    Participants will enter a 5-week participation phase, which includes 3 preparatory sessions, 2 dosing days, and 4 integration sessions.

    Drug: Psilocybin 15mg · Drug: Psilocybin 25mg

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant.

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session.

06

What researchers measure

Primary outcomes

  1. Safety of psilocybin-assisted therapy for PTSD

    Safety as measured by Adverse Event Reporting

    Time frame: Baseline to 6-month follow up

  2. Safety of psilocybin-assisted therapy for PTSD

    Safety as measured by changes in suicidal ideation on the Columbia Suicide Safety Rating Scale (CSSRS). This section of the measure is assessed on a scale of 0 to 25, with higher scores indicating greater intensity of suicidal ideation.

    Time frame: Baseline to 6-month follow up

  3. Efficacy of psilocybin-assisted therapy for PTSD

    Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms.

    Time frame: Baseline to 6-month follow up

Secondary outcomes

  1. Self-reported clinical efficacy of psilocybin-assisted therapy for PTSD symptoms

    Change in self-reported PTSD Checklist 5 (PCL-5) scores. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms.

    Time frame: Baseline to 6-month follow up

  2. Self-reported clinical efficacy of psilocybin-assisted therapy for depressive symptoms

    Changes in self-reported Quick Inventory of Depression Severity (QIDS) scores. This measure is assessed on a scale of 0 to 27, with higher scores reflecting increased severity of depressive symptoms.

    Time frame: Baseline to 6-month follow up

  3. Self-reported clinical efficacy of psilocybin-assisted therapy for anxiety symptoms

    Changes in self-reported Generalized Anxiety Disorder-7 (GAD-7) scores. This measure is assessed on a scale of 0 to 21, with higher scores reflecting increased severity of anxiety symptoms.

    Time frame: Baseline to 6-month follow up

Other outcomes

  1. Changes in Resting-State Functional Connectivity

    The effect of psilocybin-assisted therapy on functional connectivity networks using resting-state functional magnetic resonance imaging (MRI)

    Time frame: Baseline to 6-month follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 22 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 21, 2025
StartActual
Jan 30, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888128
Collaborators
Texas Department of State Health Services, Usona Institute, AIM Youth Mental Health
Responsible party
Lynnette Astrid Averill (Associate Professor, Baylor College of Medicine) — Principal investigator
First posted
Mar 21, 2025
Start date
Jan 30, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Lynnette A. Averill, Ph.D.
Contact
emerging@bcm.edu
‪(832) 271-6615

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion